Traditional therapeutic interventions against abnormal gene expression in disease states at
the level of expressed proteins are becoming increasingly difficult due to poor selectivity, off …

Potent knockdown of pathogenic RNA in vivo is an urgent health need unmet by both small-
molecule and biologic drugs.'Smart'supramolecular assembly of catalysts offers precise …

Described here is a new class of peptidyl–oligonucleotide conjugates (POCs) which show
efficient cleavage of a target RNA in a sequence-specific manner. Through …

The RNA cleaving catalyst tris (2-aminobenzimidazole) when attached to the 5'terminus of
oligonucleotides cuts complementary RNA strands in a highly site-specific manner …

Antisense sequence-specific knockdown of pathogenic RNA offers opportunities to find new
solutions for therapeutic treatments. However, to gain a desired therapeutic effect, the …

The syntheses and RNA cleavage efficiencies of a new series of oligonucleotide conjugates
of Cu (II)− serinol− terpyridine and 1, 3-propanediol are reported. These reagents, termed …

Sequence-specific protein-based ribonucleases are not found in nature. Absolute sequence
selectivity in RNA cleavage in vivo normally requires multi-component complexes that recruit …

RNA-targeting therapeutics require highly efficient sequence-specific devices capable of
RNA irreversible degradation in vivo. The most developed methods of sequence-specific …

Hydrolysis-resistant 3′-peptidyl–RNA conjugates that mimic tRNA termini represent a
remarkable synthetic challenge, particularly if they contain amino acids with complex side …

Conjugation of short peptide nucleic acids (PNA) with tetralysine peptides strongly
enhanced triple helical binding to RNA at physiologically relevant conditions. The PNA …